GlobeNewswire Inc | Jun 15, 2021 01:30AM EDT

June 15, 2021

LYON, France, June 15, 2021 (GLOBE NEWSWIRE) -- ADOCIA (Euronext Paris: FR0011184241 ADOC), a clinical-stage biopharmaceutical company specializing in the development of innovative formulations of proteins and peptides, announced today Adocia will have an oral presentation on the bi-hormonal treatment M1Pram (ADO09) at the 81st Scientific Sessions of the American Diabetes Association which will be held June 25-29, 2021, as a virtual event.

Topline results of this positive study were shared in a press release distributed on September 15, 2020.

In this oral presentation, Gregory Meiffren, Clinical Development Director at Adocia will present the study and its key results.

Date & Time: Sun, Jun 27 (Eastern)- 4:00pm - 4:15pmTitle: 197-OR - ADO09, a Coformulation of Insulin A21G and Pramlintide (Pram),Improves Blood Glucose Control and Reduces Body Weight in Subjects with T1DSpeaker: Grgory Meiffren, PhDDuration: 15 minADA Program

Adocia is currently studying M1Pram in a Phase 2 study, with results expected in Q2 2022.

About the American Diabetes Association Scientific Sessions

The American Diabetes Associations Scientific Sessions offer researchers and health care professionals from around the globe an exclusive opportunity to share ideas and gain knowledge about the recent advances in diabetes research, treatment and care. Attendees will have access to more than 3,000 original research presentations, take part in thought-provoking speaking engagements with leading diabetes experts, and expand their professional networks.

About Adocia

ADOCIA is a clinical-stage biotechnology company that specializes in the development of innovative formulations of therapeutic proteins and peptides for the treatment of diabetes, obesity and metabolic diseases. In the diabetes field, Adocias portfolio of injectable treatments is among the largest and most differentiated of the industry, featuring five clinical-stage products and several pre-clinical products. The proprietary BioChaperone technological platform is designed to enhance the effectiveness and/or safety of therapeutic proteins while making them easier for patients to use. Adocia customizes BioChaperone to each protein for a given application.

Adocias clinical pipeline includes four novel insulin formulations for prandial treatment of diabetes: two ultra-rapid formulations of insulin analog lispro (BioChaperone Lispro U100 and U200), a combination of basal insulin glargine and rapid acting insulin lispro (BioChaperone Combo) and one combination of a prandial insulin with amylin analog pramlintide M1Pram. The clinical pipeline also includes an aqueous formulation of human glucagon (BioChaperone Glucagon) for the treatment of hypoglycemia.

Adocias preclinical pipeline for diabetes treatment includes bi-hormonal combinations: two combinations of rapid acting insulin analogs and Pramlintide (BioChaperone Lispro Pram and BioChaperone Aspart Pram), and a combination of insulin glargine with GLP-1 receptor agonists (BioChaperone Glargine Liraglutide).

Adocia recently added a cell therapy initiative focused on development of a hydrogel scaffold for use in people with type 1 diabetes. The first patent application supporting this program has been filed.

Adocias preclinical pipeline for the treatment of obesity includes two bi-hormonal products: a combination of glucagon and exenatide (BioChaperone Glucagon Exenatide) and a combination of pramlintide and exenatide (PramExe).

Contact Adocia

Adocia MC Services AG The Ruth GroupGrard Soula Adocia Press Relations Adocia Investor RelationsCEO Europe USAcontactinvestisseurs@adocia.com Raimund Gabriel James SaliernoPh: +33 4 72 610610 Managing Partner Vice-Presidentwww.adocia.com adocia@mc-services.eu jsalierno@theruthgroup.com Ph: +49 89 210 228 0 Ph.: +1 646 536 7035

Disclaimer

This press release contains certain conditions financial markets and theforward-looking statements concerning markets in which Adocia operates. TheAdocia and its business. Such forward-looking statements containedforward-looking statements are based in this press release are also subjecton assumptions that Adocia considers to risks not yet known to Adocia orto be reasonable. However, there can not currently considered material bybe no assurance that the estimates Adocia. The occurrence of all or partcontained in such forward-looking of such risks could cause actualstatements will be verified, which results, financial conditions,estimates are subject to numerous performance, or achievements of Adociarisks including the risks set forth in to be materially different from suchthe ?Risk Factors? section of the forward-looking statements. This pressUniversal Registration Document filed release and the information containedwith the French Autorit des marchs herein do not constitute an offer tofinanciers on April 20, 2021 (a copy sell or the solicitation of an offerof which is available at to buy Adocia shares in anywww.adocia.com) and to the development jurisdiction.of economic